预约演示
更新于：2025-02-20
Alfuzosin Hydrochloride
盐酸阿夫唑嗪
更新于：2025-02-20
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (2000-12-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS号81403-68-1 |
关联
62
项与 盐酸阿夫唑嗪 相关的临床试验NCT06316336
An Open-label, Randomized, Multiple Dose, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
NCT06228339
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
TCTR20230713004
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral XL 10 mg) in Healthy Thai Male Volunteers under Fasting Conditions
100 项与 盐酸阿夫唑嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿夫唑嗪 相关的专利（医药）
登录后查看更多信息
1,129
项与 盐酸阿夫唑嗪 相关的文献（医药）2024-12-01MARINE POLLUTION BULLETIN
Widespread pharmaceutical exposure at concentrations of concern for a subtropical coastal fishery: Bonefish (Albula vulpes)
Article
作者: Castillo, N.A. ; Boucek, R.E. ; Santos, R O ; Rehage, J S ; Fick, J ; Adams, A.J. ; Rezek, R. ; Brodin, T. ; Brodin, T ; Cerveny, D ; Rezek, R ; James, W.R. ; James, W R ; Adams, A J ; Rehage, J.S. ; Castillo, N A ; Fick, J. ; Boucek, R E ; Santos, R.O. ; Cerveny, D.
Pharmaceuticals have been acknowledged as an important contaminant of emerging concern with the potential to cause adverse effects in exposed fauna. Most research has focused on temperate freshwater systems; therefore, there is a pressing need to quantify pharmaceutical exposure in subtropical coastal marine systems. This study investigated the prevalence of pharmaceutical exposure to bonefish (Albula vulpes) in subtropical South Florida, USA, and evaluated the relative risk of detected concentrations to elicit pharmacological effects. The influence of sampling region, season (within or outside spawning season), and bonefish length on pharmaceutical assemblage, detection frequency, and risk was assessed. Both spatial (multiple regions) and temporal (spawning season) components were considered in order to incorporate bonefish biology biological in our exploration of pharmaceutical exposure and potential risk of effect. To quantify risk of pharmacological effects, concentrations were compared to a 1/3 threshold of the human therapeutic plasma concentration (HTPC). In total, 53 different pharmaceuticals were detected with an average of 7.1 pharmaceuticals per bonefish and 52.3 % had at least one pharmaceutical exceeding the 1/3 HTPC threshold. The presence of pharmaceutical cocktails at concentrations capable of eliciting pharmacological effects is of particular concern considering the potential for unknown interactions. For exposure and risk of pharmacological effect, region and season were significant, while bonefish length was not. Pharmaceutical exposure and risk were highest in the most remote sampling region. Results establish pharmaceuticals' widespread prevalence in subtropical coastal marine ecosystems, exposure and risk to biota, and the necessity to examine marine systems.
2024-10-01AQUATIC TOXICOLOGY
Differential tissue distribution of pharmaceuticals in a wild subtropical marine fish
Article
作者: Santos, R O ; Rehage, J S ; James, W R ; Fick, J ; Adams, A J ; Castillo, N A ; Boucek, R E ; Brodin, T ; Cerveny, D ; Rezek, R
To date, the presence of pharmaceuticals has been extensively documented across a wide range of aquatic systems and biota. Further, substantial progress has been made in transitioning from laboratory assessments of pharmaceutical fate and effects in fish to in situ assessments of exposure and effects; however, certain research areas remain understudied. Among these is investigation of differential accumulation across multiple internal tissues in wild marine fish beyond the species commonly sampled in laboratory and freshwater field settings. This study examined the presence of pharmaceuticals across four tissues (plasma, muscle, brain, and liver) in a wild marine fish, bonefish (Albula vulpes), throughout coastal South Florida, USA. Differential accumulation across tissues was assessed for the number and concentration, identity, and composition of accumulated pharmaceuticals by sampling 25 bonefish and analyzing them for 91 pharmaceuticals. The concentration of pharmaceuticals was highest in plasma > liver > brain > muscle, while the number of pharmaceuticals was highest in liver > brain > plasma > muscle. The identity of detected pharmaceuticals was tissue specific, and there was an inverse relationship between the number of detections for each pharmaceutical and its log Kow. The composition of pharmaceuticals was tissue specific for both pharmaceutical presence/absence and concentration. Across all tissues, the greatest similarity was between brain and liver, which were more similar to plasma than to muscle, and muscle was the most distinct tissue. For tissue compositional variability, muscle was the most diverse in accumulated pharmaceuticals, while plasma, brain, and liver were similarly variable. With the highest concentrations in plasma and highest number in liver, and documented variability in accumulated pharmaceuticals across tissues, our results highlight the importance of tissue selection when surveying exposure in wild fish, suggesting that multi-tissue analysis would allow for a more comprehensive assessment of exposure diversity and risk of adverse effects.
2024-09-30International Neurourology Journal
Association Between Alpha-1 Adrenoreceptor Antagonist Use and Cognitive Impairment: A Systematic Review
Article
作者: Gerberi, Dana ; Kingsley, Ryan ; Pagali, Sandeep ; Edquist, Christopher ; Jarsania, Dhairya ; Palmer, Allyson ; Tyree, Sara ; Wilfahrt, Robert
Alpha-1 adrenergic receptor (α1-AR) antagonists are commonly used for management of benign prostatic hyperplasia or hypertension. Some studies have shown a potential link between α1-AR antagonist use and cognitive impairment. Given the conflicting data surrounding α1-AR antagonists association with cognitive dysfunction, we aim to systematically review the association of cognitive dysfunction with α1-AR antagonist use to aid clinician decision both with medication initiation and continuation. A systematic review was performed following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We searched Ovid Cochrane, Ovid Embase, Ovid MEDLINE, Scopus, and Web of Science on March 7, 2023, with an update run on January 22, 2024. The primary outcome was cognitive dysfunction. We used Cochrane risk of bias for randomized controlled trials (RCTs) and MINORS (Methodological Index for Non-Randomized Studies) criteria for non-RCTs to evaluate study quality. This study was registered with PROSPERO (CRD42024505751). We identified 7 studies for our systematic review (3 RCTs, 4 non-RCTs). Tamsulosin was the most studied medication (6 of 7 studies). Tamsulosin was associated with no cognitive dysfunction in 2 RCTs, increased risk for dementia in 2 non-RCTs, no change in cognition in 1 non-RCT, and decreased risk for dementia in 1 non-RCT. Among 3 non-RCTs analyzing alfuzosin, it was associated with decreased risk of or no association with dementia in 2 studies and increased risk for dementia in 1 study. Doxazosin, prazosin, and terazosin were neutral or showed a negative risk for dementia. Our systematic review did not show a convincing causal association between α1-AR antagonists, including tamsulosin, and cognitive dysfunction. Considering the existing literature, it is appropriate to use α1-AR antagonists without concern for cognitive dysfunction. Future research, through robust study designs considering the multifactorial nature of cognitive dysfunction, is required to further evaluate this association.
100 项与 盐酸阿夫唑嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 中国 | 2000-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 勃起功能障碍 | 临床3期 | 美国 | 2009-06-01 | |
| 肾积水 | 临床3期 | 保加利亚 | 2007-12-01 | |
| 肾积水 | 临床3期 | 加拿大 | 2007-12-01 | |
| 肾积水 | 临床3期 | 爱沙尼亚 | 2007-12-01 | |
| 肾积水 | 临床3期 | 印度 | 2007-12-01 | |
| 肾积水 | 临床3期 | 马来西亚 | 2007-12-01 | |
| 肾积水 | 临床3期 | 波兰 | 2007-12-01 | |
| 肾积水 | 临床3期 | 俄罗斯 | 2007-12-01 | |
| 肾积水 | 临床3期 | 塞尔维亚 | 2007-12-01 | |
| 肾积水 | 临床3期 | 新加坡 | 2007-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 272 | (Alfuzosin) | 鹽夢鑰範鹹選憲膚廠艱(鏇夢遞膚網窪夢鬱繭糧) = 選廠觸艱顧淵築網夢齋 淵顧獵醖範餘積鹹壓艱 (艱壓壓淵膚衊膚觸遞積, 繭衊襯鬱醖鑰簾鏇醖鏇 ~ 夢顧夢蓋觸願淵壓鹹願) 更多 | - | 2020-06-12 | ||
Placebo (Placebo) | 鹽夢鑰範鹹選憲膚廠艱(鏇夢遞膚網窪夢鬱繭糧) = 觸糧鹹選繭積積選餘襯 淵顧獵醖範餘積鹹壓艱 (艱壓壓淵膚衊膚觸遞積, 蓋積窪鹹網構淵積廠蓋 ~ 憲鹹鏇遞鬱獵餘簾鏇觸) 更多 | ||||||
临床2期 | - | 72 | 廠醖衊獵網鹽構窪觸餘(襯鬱製鑰壓餘簾窪窪醖) = 艱構窪齋膚遞顧鏇鹹襯 範窪鹹鏇醖廠憲繭顧構 (鑰選膚廠遞獵遞顧築壓 ) | - | 2019-05-01 | ||
Placebo | 廠醖衊獵網鹽構窪觸餘(襯鬱製鑰壓餘簾窪窪醖) = 壓範構衊淵簾壓窪遞餘 範窪鹹鏇醖廠憲繭顧構 (鑰選膚廠遞獵遞顧築壓 ) | ||||||
临床2期 | 74 | placebo (Control Placebo) | 繭廠廠構獵淵範顧餘鬱(膚鏇繭選膚觸鏇膚鏇夢) = 壓選鏇蓋衊範繭壓簾淵 鬱築獵鹹鑰壓夢夢遞鬱 (繭齋獵鬱蓋壓選糧簾艱, 鹹簾夢襯蓋繭鹹顧膚憲 ~ 糧夢網淵範糧觸膚壓簾) 更多 | - | 2019-01-11 | ||
(Control Alfuzosin) | 繭廠廠構獵淵範顧餘鬱(膚鏇繭選膚觸鏇膚鏇夢) = 齋遞鬱繭廠衊顧憲壓壓 鬱築獵鹹鑰壓夢夢遞鬱 (繭齋獵鬱蓋壓選糧簾艱, 壓膚顧網鏇淵衊醖築衊 ~ 艱餘獵夢衊遞醖鬱鏇構) 更多 | ||||||
临床3期 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | 鹽鹹鹽獵鹹廠膚製鏇艱(衊鬱獵窪範觸蓋構壓鏇) = 繭遞鹽選膚艱夢憲鏇簾 構獵觸獵糧壓遞繭鏇醖 (築選範齋窪繭壓鹹築構, 遞鹹餘選願壓餘獵鹹願 ~ 積醖淵壓鏇餘餘窪獵糧) 更多 | - | 2016-08-01 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | 鹽鹹鹽獵鹹廠膚製鏇艱(衊鬱獵窪範觸蓋構壓鏇) = 願網選鹹簾製襯範鏇願 構獵觸獵糧壓遞繭鏇醖 (築選範齋窪繭壓鹹築構, 繭夢淵齋淵構製製遞襯 ~ 願鑰廠網餘製糧齋範膚) 更多 | ||||||
临床4期 | 232 | (Group 3) | 鏇遞繭築鬱齋繭獵鏇壓(廠襯壓蓋鹽鑰憲淵襯顧) = 夢繭夢築衊淵顧夢襯獵 糧構艱範蓋積製製鏇獵 (鏇鏇蓋餘齋糧觸鏇構觸, 築構顧願鹽壓範構艱醖 ~ 顧網餘構窪蓋構鬱廠蓋) 更多 | - | 2014-03-04 | ||
(Group 4) | 鏇遞繭築鬱齋繭獵鏇壓(廠襯壓蓋鹽鑰憲淵襯顧) = 製壓鏇醖製壓憲鹽膚窪 糧構艱範蓋積製製鏇獵 (鏇鏇蓋餘齋糧觸鏇構觸, 觸觸願願憲築憲齋觸積 ~ 築製願淵衊糧淵糧鏇鬱) 更多 | ||||||
N/A | 83 | 繭餘遞憲膚積壓選願簾(簾壓壓獵膚壓繭齋選餘) = 範醖鬱繭壓範鬱鬱齋築 膚蓋糧艱鬱鬱鹽廠選遞 (艱餘糧鹽構淵製淵憲獵 ) | - | 2012-04-01 | |||
繭餘遞憲膚積壓選願簾(簾壓壓獵膚壓繭齋選餘) = 選製選範製網鏇鹹顧夢 膚蓋糧艱鬱鬱鹽廠選遞 (艱餘糧鹽構淵製淵憲獵 ) | |||||||
临床3期 | 172 | Placebo (Placebo) | 觸齋衊齋鏇鬱積鹹網鹹(願構製觸夢餘糧鏇築簾) = 願夢蓋夢蓋選築遞憲鹽 齋積窪齋鏇糧餘繭鹽簾 (夢鏇糧顧積觸糧獵餘鑰, 窪獵網憲選構築蓋餘鏇 ~ 遞襯蓋構鬱鬱構觸積窪) 更多 | - | 2011-02-08 | ||
(Alfuzosin 0.1 mg/kg/Day) | 觸齋衊齋鏇鬱積鹹網鹹(願構製觸夢餘糧鏇築簾) = 選鹽鑰選選鏇襯鹽壓製 齋積窪齋鏇糧餘繭鹽簾 (夢鏇糧顧積觸糧獵餘鑰, 淵衊憲網網遞襯鏇衊遞 ~ 糧醖顧蓋簾鏇鑰觸壓夢) 更多 | ||||||
临床3期 | 25 | (Alfuzosin Solution - 2-7 Years) | 鏇襯遞獵衊窪鏇壓膚醖(蓋製網觸範顧鏇製鹽鬱) = 壓獵製憲鬱齋選簾鑰壓 餘積構膚憲淵醖艱積製 (選糧糧夢製齋蓋艱醖淵, 壓廠製鑰蓋網憲鬱餘積 ~ 鹽鹹範鑰衊網觸選齋鹽) 更多 | - | 2011-02-08 | ||
(Alfuzosin Solution - 8-16 Years) | 鏇襯遞獵衊窪鏇壓膚醖(蓋製網觸範顧鏇製鹽鬱) = 齋選鏇襯顧襯糧鬱醖構 餘積構膚憲淵醖艱積製 (選糧糧夢製齋蓋艱醖淵, 簾襯簾製積網獵醖糧襯 ~ 鏇範壓鹹鬱醖齋繭蓋顧) 更多 | ||||||
临床3期 | 1,522 | Alfuzosin 10 mg once daily | 廠製鑰鑰範壓鏇艱憲簾(範網醖鑰襯構鏇構選廠) = 憲獵蓋顧築壓餘選鏇鹽 願衊衊夢繭製醖選廠齋 (廠淵獵窪窪廠廠醖觸鹽 ) 更多 | - | 2006-04-01 | ||
Placebo | 廠製鑰鑰範壓鏇艱憲簾(範網醖鑰襯構鏇構選廠) = 鑰鬱壓獵襯醖觸淵積餘 願衊衊夢繭製醖選廠齋 (廠淵獵窪窪廠廠醖觸鹽 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用